Aurobindo Pharma's subsidiary, Acrotech Biopharma, announced the launch of the ointment Adquey in the US market, thereby entering the American dermatology market. In connection with this launch and plans to expand this therapeutic segment, the company has created a specialized dermatology division.
According to regulatory documentation, the drug is a non-steroidal topical agent intended for the treatment of mild to moderate atopic dermatitis in adult patients, as well as in children over two years old. Aurobindo Pharma reported that the original drug was developed by Otsuka Pharmaceutical and subsequently licensed to Acrotech Biopharma for commercialization in the United States.
This product is expected to compete in a market valued at approximately $1.3 billion USD for the 12 months ending in July 2026, according to IQVIA MAT. Ashish Anvekar, President of Acrotech Biopharma, noted that the launch of Adquey represents a significant achievement for Acrotech and marks the beginning of entry into the US dermatology market with a differentiated treatment option.
Acrotech Biopharma operates as a subsidiary of Aurobindo Pharma Ltd and was established as a global platform for the commercialization of innovative patented pharmaceuticals.
